A trial to assess induction therapy with alemtuzumab versus basiliximab, followed by a three drug immunosuppression regimen, in patients undergoing a single, or double, lung transplant, or a combined heart-lung transplant.
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2014
At a glance
- Drugs Alemtuzumab (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate
- Indications Heart-lung transplant rejection; Lung transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 15 Sep 2014 New trial record